Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097624 | 1.00 | KDM4E (0.36) | KDM4ELMNAL3MBTL1TDP1 | |
| SCHEMBL2097031 | 1.00 | KDM4E (0.36) | KDM4ELMNAL3MBTL1TDP1 | |
| SCHEMBL2093150 | 0.97 | KDM4E (0.40) | KDM4ELMNAL3MBTL1TDP1 | |
| SCHEMBL2091754 | 0.97 | KDM4E (0.40) | KDM4ELMNAL3MBTL1TDP1 | |
| SCHEMBL2094480 | 0.82 | KDM4E (0.31) | KDM4E | |
| SCHEMBL2095074 | 0.81 | KDM4E (0.42) | KDM4E | |
| SCHEMBL11003487 | 0.76 | KDM4E (0.50) | KDM4ELMNAL3MBTL1TDP1 | |
| SCHEMBL2091780 | 0.72 | KDM4E (0.41) | KDM4E | |
| SCHEMBL6927937 | 0.72 | HTT (0.32) | KDM4E | |
| SCHEMBL10999193 | 0.72 | KDM4E (0.59) | KDM4ELMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | claimed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | KDM4E 4269/4885LMNA 2661/4885L3MBTL1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.